Kuwait MOH Dermatology Exam: Official Blueprint & Preparation
The Kuwait Ministry of Health dermatology licensing exam, administered by Prometric, is sat by dermatologists applying for a specialist license in Kuwait. It assesses the ability to diagnose and manage the full spectrum of skin, hair, nail and mucosal disease in adults and children, and to recognize when skin findings signal serious systemic illness.
- Questions150 MCQs
- Time170 min + 10 min break
- Pass markRegistrar 65% · Senior 70%
- Attempts3, 6 weeks apart
Dermatology: Kuwait licensing facts
| Specialty | Dermatology |
|---|---|
| Professional category | Medical |
| Licensing authority | Kuwait Ministry of Health — Medical Licensing Department |
| Official exam | Kuwait Licensing Exam — Dermatology |
| Exam provider | Prometric (worldwide test centres) |
| Blueprint status | Official Prometric blueprint Official Prometric blueprint: 150 MCQs, 170 min, pass mark Registrar 65% · Senior 70%. |
| Questions | 150 multiple-choice questions |
| Duration | 170 min plus a 10-minute break |
| Passing score | Registrar 65% · Senior 70% |
| Attempts | 3 attempts, at least 6 weeks apart |
| Language | Not stated in official documents |
| Source | Prometric “Kuwait Licensing Exam” document |
| Last verified |
The Prometric document describes 150 computer-based multiple-choice questions completed in 170 minutes, with a separate 10-minute break. Candidates need 65% to pass at Registrar level and 70% at Senior level, and up to three attempts are allowed with a minimum of six weeks between attempts. Questions are usually clinical vignettes describing morphology, distribution, histopathology or laboratory results, so strong pattern recognition and knowledge of current therapy are both essential.
The official blueprint contains thirteen sections. Cutaneous Neoplasms is the largest at 21%, closely followed by Papulosquamous and Eczematous Dermatoses at 20%. Pediatric Dermatology and Procedural Dermatology also carry substantial weight, while connective tissue disease, systemic disease, infections and vesiculobullous disorders form the middle tier. Patient Safety and Professionalism and Ethics each account for 7%, so together they are worth as much as some clinical sections. Content is subject to change upon department review, according to the document, so check the latest version before booking. Use the weights below to plan your revision, and work through the high-yield topics and practice questions for each domain.
Dermatology exam blueprint: questions per section
| # | Section | Questions | % of exam |
|---|---|---|---|
| 1 | Papulosquamous and Eczematous Dermatoses | 20 | 13.3% |
| 2 | Urticaria, Erythemas, Purpura and Connective Tissue Diseases | 12 | 8% |
| 3 | Vesiculobullous Disorders | 8 | 5.3% |
| 4 | Adnexal, Hair, Nails and Mucous Membrane Diseases | 8 | 5.3% |
| 5 | Metabolic and Systemic Diseases, Dermal Connective Tissue and Subcutaneous Fat | 12 | 8% |
| 6 | Infections | 12 | 8% |
| 7 | Cutaneous Neoplasms | 21 | 14% |
| 8 | Pediatric Dermatology | 15 | 10% |
| 9 | Procedural Dermatology | 14 | 9.3% |
| 10 | Skin Manifestations of Other Diseases | 7 | 4.7% |
| 11 | Pigmentary Disorders and Photodermatoses | 7 | 4.7% |
| 12 | Patient Safety | 7 | 4.7% |
| 13 | Professionalism and Ethics | 7 | 4.7% |
| Total | 150 | 100% |
Source: Prometric “Kuwait Licensing Exam”, verified 1 November 2026. Section totals checked to equal 150. Prometric notes that content, percentages and attempts are subject to change upon department review.
Section-by-section high-yield topics
1Papulosquamous and Eczematous Dermatoses 20 Q · 13.3%
Covers psoriasis, lichenoid eruptions and eczematous conditions, including systemic and biologic therapy.
- Psoriasis subtypes, comorbidities and severity scoring
- Biologic therapy for psoriasis: TNF, IL-17 and IL-23 inhibitors and pre-treatment screening
- Methotrexate and cyclosporine monitoring
- Atopic dermatitis: topical therapy, dupilumab and JAK inhibitors
- Allergic and irritant contact dermatitis and patch testing
- Lichen planus and lichenoid drug eruptions
- Seborrheic dermatitis
- Pityriasis rosea
- Erythroderma: causes and management
2Urticaria, Erythemas, Purpura and Connective Tissue Diseases 12 Q · 8%
Assesses urticaria, reactive erythemas, severe drug reactions, vasculitis and autoimmune connective tissue disease.
- Chronic spontaneous urticaria: antihistamine updosing and omalizumab
- Erythema multiforme and its herpes simplex association
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- DRESS syndrome
- Cutaneous small-vessel vasculitis and IgA vasculitis
- Cutaneous lupus erythematosus
- Dermatomyositis and malignancy screening
- Systemic sclerosis and morphea
- Erythema nodosum
3Vesiculobullous Disorders 8 Q · 5.3%
Tests the autoimmune and inherited blistering diseases, with emphasis on immunofluorescence and treatment.
- Pemphigus vulgaris and pemphigus foliaceus
- Rituximab in pemphigus
- Bullous pemphigoid diagnosis and treatment
- Direct and indirect immunofluorescence patterns
- Dermatitis herpetiformis and gluten sensitivity
- Mucous membrane pemphigoid
- Linear IgA bullous dermatosis
- Epidermolysis bullosa subtypes
4Adnexal, Hair, Nails and Mucous Membrane Diseases 8 Q · 5.3%
Covers disorders of the pilosebaceous unit, sweat glands, hair, nails and oral and genital mucosa.
- Acne vulgaris and isotretinoin monitoring
- Rosacea subtypes and treatment
- Hidradenitis suppurativa staging and biologics
- Alopecia areata and JAK inhibitors
- Androgenetic alopecia and telogen effluvium
- Scarring alopecias
- Nail psoriasis and onychomycosis
- Oral lichen planus and aphthous ulcers
- Lichen sclerosus
5Metabolic and Systemic Diseases, Dermal Connective Tissue and Subcutaneous Fat 12 Q · 8%
Assesses skin findings in metabolic disease, deposition disorders, dermal connective tissue disorders and panniculitis.
- Necrobiosis lipoidica and other diabetic skin signs
- Porphyria cutanea tarda
- Cutaneous sarcoidosis
- Amyloidosis
- Xanthomas and lipid disorders
- Ehlers-Danlos syndrome and pseudoxanthoma elasticum
- Calciphylaxis
- Panniculitis classification
- Granuloma annulare
6Infections 12 Q · 8%
Covers bacterial, viral, fungal and parasitic skin infections, including those common in the Gulf region.
- Cutaneous leishmaniasis diagnosis and treatment
- Impetigo, cellulitis and necrotizing fasciitis
- Dermatophyte infections and tinea capitis
- Scabies and treatment of contacts
- Herpes zoster and antiviral therapy
- Leprosy classification
- Cutaneous tuberculosis
- Syphilis manifestations and serology
- Molluscum contagiosum and warts
7Cutaneous Neoplasms 21 Q · 14%
The largest section, covering benign and malignant skin tumors, staging and management.
- Melanoma: Breslow depth, AJCC staging, excision margins and sentinel lymph node biopsy
- Dermoscopy of melanocytic lesions
- Basal cell carcinoma subtypes and treatment
- Squamous cell carcinoma high-risk features
- Actinic keratosis field therapy
- Merkel cell carcinoma
- Mycosis fungoides staging
- Kaposi sarcoma
- Seborrheic keratosis and benign adnexal tumors
8Pediatric Dermatology 15 Q · 10%
Tests neonatal and childhood skin disease, vascular anomalies and genodermatoses.
- Infantile hemangioma and propranolol therapy
- PHACE syndrome
- Port-wine stain and Sturge-Weber syndrome
- Neurofibromatosis type 1 diagnostic criteria
- Tuberous sclerosis complex
- Transient neonatal dermatoses
- Staphylococcal scalded skin syndrome
- Viral exanthems and hand, foot and mouth disease
- Kawasaki disease skin and mucosal findings
9Procedural Dermatology 14 Q · 9.3%
Covers dermatologic surgery, lasers, cosmetic procedures and their complications.
- Mohs micrographic surgery indications
- Local anesthesia and maximum safe doses
- Wound closure, flaps and grafts
- Cryotherapy and electrosurgery
- Laser-tissue interaction and selective photothermolysis
- Botulinum toxin and filler complications including vascular occlusion
- Chemical peels
- Antibiotic prophylaxis and bleeding risk in dermatologic surgery
10Skin Manifestations of Other Diseases 7 Q · 4.7%
Assesses cutaneous signs of internal disease and paraneoplastic syndromes.
- Pyoderma gangrenosum and inflammatory bowel disease
- Acanthosis nigricans and malignancy
- Paraneoplastic pemphigus
- Sweet syndrome
- Cutaneous signs of HIV infection
- Skin findings in renal and liver disease
- Graft-versus-host disease
11Pigmentary Disorders and Photodermatoses 7 Q · 4.7%
Covers disorders of pigmentation and photosensitivity, and their treatment.
- Vitiligo: topical therapy, phototherapy and JAK inhibitors
- Melasma and hydroquinone use
- Post-inflammatory hyperpigmentation in skin of color
- Polymorphic light eruption
- Phototoxic versus photoallergic reactions
- Xeroderma pigmentosum
- Phototherapy: narrowband UVB and PUVA
12Patient Safety 7 Q · 4.7%
Tests safe prescribing, procedural safety and error prevention in dermatology.
- Isotretinoin pregnancy prevention programs
- Monitoring of systemic immunosuppressants
- Specimen labeling and correct-site surgery
- Infection control in procedures
- Teledermatology safety
- Incident reporting and learning from errors
13Professionalism and Ethics 7 Q · 4.7%
Assesses consent, confidentiality and ethical issues, including those specific to cosmetic practice.
- Informed consent for procedures and cosmetic treatments
- Clinical photography and confidentiality
- Managing unrealistic expectations and body dysmorphic disorder
- Advertising and conflicts of interest
- Disclosure of adverse outcomes
- Respectful communication across cultures
High-yield topics & competencies
Must-know topics
- Cutaneous Neoplasms (21%) and Papulosquamous and Eczematous Dermatoses (20%) together make up over 40% of the exam.
- Melanoma management depends on Breslow depth: discuss sentinel lymph node biopsy for tumors thicker than 0.8 mm or ulcerated.
- In SJS/TEN, immediately stop the culprit drug; common culprits include allopurinol, aromatic anticonvulsants, sulfonamides and nevirapine.
- Bullous pemphigoid: linear IgG and C3 along the basement membrane; superpotent topical steroids are effective first-line therapy.
- Pemphigus vulgaris: intercellular IgG; rituximab with corticosteroids is a first-line option.
- Screen for tuberculosis and hepatitis before starting biologics for psoriasis.
- Propranolol is first-line for complicated infantile hemangioma; evaluate segmental facial lesions for PHACE.
- Isotretinoin requires a strict pregnancy prevention program.
- Cutaneous leishmaniasis is an important infection to recognize in the region.
- Patient Safety and Professionalism and Ethics together account for 14% of the exam.
Competencies assessed
- Accurate morphologic diagnosis and construction of differential diagnoses
- Interpretation of histopathology, immunofluorescence and dermoscopy
- Safe selection and monitoring of topical, systemic and biologic therapies
- Recognition of dermatologic emergencies and cutaneous signs of systemic disease
- Appropriate procedural and surgical management of skin tumors
- Ethical, patient-centered practice, including in cosmetic dermatology
How to prepare for the Dermatology exam
Allocate study time in proportion to the blueprint, giving cutaneous neoplasms and papulosquamous and eczematous disease about two-fifths of your hours, followed by pediatric and procedural dermatology. Use Bolognia or Fitzpatrick as your core text and Wolverton for drug dosing, monitoring and adverse effects, which are frequently tested. Review clinical images, dermoscopy patterns and immunofluorescence findings regularly, since many questions depend on visual recognition described in words. Complete timed MCQ blocks and track your accuracy by section to direct revision to weaker areas. Finish with at least one full 150-question mock under the 170-minute limit.
How our question bank is weighted
Practice questions follow the official section percentages:
- Papulosquamous and Eczematous Dermatoses13.3%
- Urticaria, Erythemas, Purpura and Connective Tissue Diseases8%
- Vesiculobullous Disorders5.3%
- Adnexal, Hair, Nails and Mucous Membrane Diseases5.3%
- Metabolic and Systemic Diseases, Dermal Connective Tissue and Subcutaneous Fat8%
- Infections8%
- Cutaneous Neoplasms14%
- Pediatric Dermatology10%
- Procedural Dermatology9.3%
- Skin Manifestations of Other Diseases4.7%
- Pigmentary Disorders and Photodermatoses4.7%
- Patient Safety4.7%
- Professionalism and Ethics4.7%
Recommended references (from Prometric’s reference list)
- Fitzpatrick's Dermatology in General Medicine - Lowell A. Goldsmith et al. (McGraw-Hill), latest edition
- Dermatology - Jean L. Bolognia et al., latest edition
- Comprehensive Dermatologic Drug Therapy - Stephen E. Wolverton (Elsevier), latest edition
- Professionalism and Ethics: Handbook for Residents, A Practical Guide - James Ware, Abdulaziz Fahad Alkaabba, Ghaiath M.A. Hussein, Omar Hasan Kasule (SCFHS), latest edition
- Essentials of Patient Safety (SCFHS), latest edition
Dermatology sample questions
Q1. A 48-year-old man presents with fever, painful skin and a spreading rash for 2 days. Three weeks earlier he started allopurinol for gout. Examination shows dusky, atypical target lesions on the trunk with flaccid blisters and epidermal detachment involving about 8% of body surface area, together with oral, conjunctival and genital erosions. Nikolsky sign is positive. Which is the most important initial step in management?
Show answer & explanation
Correct answer: B. Mucosal involvement with epidermal detachment below 10% of body surface area after starting a high-risk drug is consistent with Stevens-Johnson syndrome. Allopurinol is one of the most common culprits, particularly in carriers of HLA-B*58:01. Prompt withdrawal of the culprit drug is the single most important intervention and improves prognosis. Patients need care in a burn or intensive care unit with wound care, fluid and nutritional support, and ophthalmology review.
- A: Continuing the culprit drug allows ongoing epidermal necrosis regardless of other treatment.
- C: Any continued exposure to the culprit drug is unsafe, and antihistamines do not treat SJS.
- D: Erythema multiforme has typical acral targets and limited detachment, and this drug-related picture is SJS.
Q2. An 82-year-old woman presents with several weeks of intense itching followed by tense blisters on her thighs, abdomen and flexural areas. Many blisters arise on urticarial plaques, and the oral mucosa is spared. Nikolsky sign is negative. Biopsy shows a subepidermal blister with eosinophils, and direct immunofluorescence shows linear IgG and C3 along the basement membrane zone. Which is the most appropriate first-line treatment?
Show answer & explanation
Correct answer: A. Elderly onset, pruritus, tense blisters on urticarial plaques and linear IgG and C3 at the basement membrane zone are diagnostic of bullous pemphigoid. Superpotent topical corticosteroids such as clobetasol are effective first-line therapy, even in extensive disease, and cause fewer systemic adverse effects than high-dose oral steroids. Doxycycline, oral corticosteroids or other immunosuppressants can be added for refractory disease. Review of possible triggering drugs such as DPP-4 inhibitors is also important.
- B: Rituximab is a first-line option for pemphigus vulgaris, not for typical bullous pemphigoid.
- C: There is no evidence of herpes virus infection in this autoimmune blistering disease.
- D: A gluten-free diet treats dermatitis herpetiformis, which shows granular IgA in dermal papillae.
Q3. A 41-year-old woman has an excisional biopsy of a changing pigmented lesion on her back. Histopathology confirms invasive melanoma with a Breslow thickness of 1.3 mm, no ulceration and clear but narrow margins. There are no palpable regional lymph nodes and she has no symptoms of metastatic disease. Which is the most appropriate next step?
Show answer & explanation
Correct answer: B. A non-ulcerated melanoma 1.01 to 2.0 mm thick is stage T2a. Current guidelines recommend wide local excision with clinical margins of 1 to 2 cm for this thickness. Sentinel lymph node biopsy is recommended for melanomas thicker than 0.8 mm, or thinner tumors with ulceration, because nodal status is the strongest prognostic factor and guides adjuvant therapy. Elective lymph node dissection without nodal evidence is no longer recommended.
- A: Margins of 0.5 cm are for melanoma in situ, and omitting SLNB misses important staging information.
- C: Margins of 3 cm and elective node dissection are not supported for a T2a melanoma.
- D: Diagnostic biopsy margins are inadequate for invasive melanoma, which needs definitive wide excision.
Original educational question written by KMLE Exam — not a recalled exam question.
Dermatology exam FAQs
How many questions are on the Kuwait MOH Dermatology exam?
The Prometric document describes the Dermatology exam as 150 computer-based multiple-choice questions, distributed across the official blueprint sections shown on this page.
How long is the Dermatology exam?
The published testing time is 170 minutes, with an additional 10-minute break. Practicing full-length timed sets helps you build the pacing needed for 150 questions.
What score do I need to pass?
The document lists a pass mark of 65% for Registrar and 70% for Senior candidates. Which threshold applies depends on the level (Registrar or Senior) you are being assessed for, so confirm your category with the licensing authority.
How many attempts are allowed?
The document allows three attempts, with a minimum of six weeks between attempts. Use the interval to strengthen the blueprint sections where your performance was weakest.
Is the blueprint fixed?
No. The Prometric document states that exam content is subject to change upon department review, so check the official document before your exam date and treat the percentages as a guide to emphasis rather than a guarantee of question counts.
Is this website the official exam provider?
No. This is an independent preparation resource and is not affiliated with the Kuwait Ministry of Health or Prometric. For fees, eligibility, registration and scheduling, contact the Kuwait MOH or Prometric directly.